stockrow
Saturday 7 November 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024.
15.78
0.93
+6.26%
Follow AKTS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| (34.45%) | — | — | — |
+3 more TTM periods Free account |
|
| (22.22%) | 0.00% | 0.00% | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(14.86%) | 0.00% | 0.00% | — | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(2.52) | (2.82) | 0.00 | (72.96) | |
Free Cash Flow |
(139.37) | (136.90) | (98.90) | (58.90) | |
Capital Expenditures |
(14.23) | (14.87) | (15.87) | (10.00) | |
| Other line items | |||||
Cash ROIC |
(13.91%) | (13.11%) | (23.89%) | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
826.24% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
212.89% | — | — | — | |
Share Based Compensation of Revenue |
93.15% | — | — | — | |
Operating CF/Net income |
1.66 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
(0.19) | (0.28) | (0.48) | 0.00 | |
Capex/Depreciation |
4.61 | 3.45 | 2.29 | 1.50 | |
Revenue per Share |
0.17 | 0.00 | — | 0.00 | |
Operating CF per Share |
(2.26) | (2.51) | 0.00 | (60.58) | |
Capex per Share |
(0.26) | (0.31) | 0.00 | (12.38) | |
Capex to Sales |
1.47 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026